Core Viewpoint - He Yuan Bio is set to launch its public offering, with a total share capital of 268 million shares and plans to issue 89.45 million shares, representing 25.02% of the post-issue total share capital [2] Company Information - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [2] - The company plans to issue shares at a price of 29.06 yuan, with a maximum subscription limit of 14,000 yuan in market value required for top-tier subscriptions [2] Fundraising Allocation - The company intends to allocate raised funds as follows: - 1.90 billion yuan for the construction of a plant-derived recombinant human serum albumin industrialization base - 793.69 million yuan for new drug research and development - 800 million yuan for working capital [2] Financial Indicators - Key financial metrics for He Yuan Bio include: - Total assets for 2024 are projected at 1.0618 billion yuan, compared to 962.20 million yuan in 2023 and 1.1027 billion yuan in 2022 - Net assets are expected to be 601.35 million yuan in 2024, down from 731.62 million yuan in 2023 and 895.26 million yuan in 2022 - Operating revenue is forecasted at 25.22 million yuan for 2024, slightly up from 24.26 million yuan in 2023 and significantly higher than 13.40 million yuan in 2022 - The company anticipates a net loss attributable to shareholders of 151.37 million yuan in 2024, an improvement from a loss of 186.96 million yuan in 2023 and 143.57 million yuan in 2022 - Research and development expenses are projected at 116.79 million yuan for 2024, with R&D expenditure as a percentage of operating revenue at 463.14% [2]

Company Overview - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [1] - The company plans to publicly issue 89.45 million shares, accounting for 25.02% of the total share capital post-issue [1] IPO Details - The subscription code for the IPO is 787765, with a subscription price set at 29.06 yuan per share [1] - The maximum subscription limit for a single account is 14,000 shares, requiring a minimum market value of 140,000 yuan in the Shanghai market [1] - The online issuance quantity is 14.31 million shares, with the subscription date on October 14, 2025, and the announcement of the winning numbers and payment date on October 16, 2025 [1] Fundraising Allocation - The company plans to allocate 1.90867 billion yuan for the construction of a plant-derived recombinant human serum albumin industrialization base [1] - An additional 793.69 million yuan is earmarked for new drug research and development [1] - 800 million yuan will be used to supplement working capital [1] Financial Performance - Total assets for 2024 are projected at 1.06181 billion yuan, an increase from 962.20 million yuan in 2023 [1] - Net assets are expected to decrease to 601.35 million yuan in 2024 from 731.62 million yuan in 2023 [1] - Operating revenue is forecasted to rise to 252.16 million yuan in 2024, compared to 242.64 million yuan in 2023 [1] - The company anticipates a net loss attributable to shareholders of 151.37 million yuan in 2024, an improvement from a loss of 186.96 million yuan in 2023 [1] - Research and development expenses are projected at 116.79 million yuan, representing 463.14% of operating revenue [1]

Group 1 - The company He Yuan Bio (688765.SH) plans to issue 89.451354 million shares, accounting for 25.02% of the total share capital after the issuance, without involving shareholder public offerings [1] - The strategic placement will include participation from CITIC Securities and Haitong Innovation Investment, with a maximum subscription amount of 240 million yuan for CITIC and an initial follow-on ratio of 5% for Haitong [1] - The initial inquiry date for the issuance is set for October 9, 2025, with subscription starting on October 14, 2025, followed by an application for stock listing on the Shanghai Stock Exchange [1] Group 2 - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform [1] - The core product HY1001 has completed domestic Phase III clinical trials, achieving both primary and secondary endpoints with good safety results [1] - The company's net profits attributable to the parent company for the years 2022 to the first half of 2025 are projected to be -143.5763 million yuan, -186.9629 million yuan, -151.3681 million yuan, and -81.6278 million yuan respectively [1] Group 3 - If the stock issuance is successful, the raised funds (after deducting issuance costs) will be invested in the construction of a recombinant human protein industrialization base, new drug research and development projects, and to supplement working capital [2]

Group 1 - The core viewpoint of the article is that Wuhan Heyuan Biotechnology Co., Ltd. has been approved for IPO by the Shanghai Stock Exchange, marking it as the 30th company to pass this year [1] - Heyuan Biotechnology is an innovative biopharmaceutical company with a leading global plant-based bioreactor technology platform, focusing on products including pharmaceuticals, pharmaceutical excipients, and research reagents [1][2] - The company plans to issue 89.45 million shares, accounting for 25.02% of the total share capital post-issue, and aims to raise 240 million yuan for projects including the construction of a human serum albumin industrialization base and new drug research and development [2] Group 2 - The controlling shareholder and actual controller of the company is Yang Daichang, who holds 40.29 million shares, representing 15.03% of the total share capital, and indirectly controls an additional 10.05 million shares, totaling 18.78% [2] - The main questions raised during the listing committee meeting included inquiries about the advanced nature of the core technologies, market space estimation for the drug HY1001, and safety compliance measures for the production of medicinal rice [3]